AbbVie, Roche post a big win with a blockbuster FDA OK for Venclexta/Rituxan combo for leukemia

The pharma giant — allied with AbbVie — says the FDA has approved a combination of Venclexta and Rituxan as a second-line therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma. This is the first chemo-free oral combination with a fixed treatment duration for CLL.